GleamWall
中文EN

IMRX Immuneering Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1790340 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.4%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.5%
ROA-31.4%
ROIC (approx.)-105.3%
Asset turnover—

Leverage & solvency

Liabilities / assets7.6%
Debt / equity0.00x
Current ratio13.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$42.05M$47.96M
SG&A expense$17.30M$16.08M
Operating income-$59.38M-$64.07M
Income tax$0—
Net income-$56.02M-$61.04M
EBITDA-$59.05M-$63.72M
EPS (basic)-1.27-2.04
EPS (diluted)-1.27-2.04
Weighted avg. shares (diluted)44.01M29.98M
Balance sheet
Cash & equivalents$128.65M$36.14M
Short-term investments—$0
Current assets$176.25M$39.59M
PP&E, net$938,481$1.12M
Goodwill$6.69M$6.69M
Intangibles$321,147$350,413
Total assets$231.99M$52.71M
Current liabilities$10.07M$7.50M
Total liabilities$13.50M$11.33M
Shareholders' equity$218.48M$41.39M
Cash flow statement
Operating cash flow-$45.34M-$55.00M
Capital expenditure$142,226$84,875
Free cash flow-$45.49M-$55.08M
Investing cash flow-$88.74M$26.43M
Financing cash flow$226.58M$5.30M
Depreciation & amortization$324,517$355,807
Stock-based compensation$6.31M$6.50M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.